Katie Ellias

Life Sciences/Medtech Investor and Independent Board Member

Katie Ellias is a seasoned healthcare investor, board member, advisor, and operator with over 20 years of experience building and investing in healthcare and life sciences companies, focused on biotechnology and medical devices. Katie was most recently a Managing Director at the T1D Fund, an evergreen, Boston-based venture philanthropy fund launched in 2017, focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through equity investments. She currently serves on the board of SAB Biotherapeutics, and has previously served on the board of DiogenX, Veralox, i2O, Biolinq, Seraxis, Enthera, GentiBio, Zag Bio, Pandion (sold to Merck), Protomer (sold to Eli Lilly), and Inversago (sold to Novo Nordisk).

Katie has been a life-sciences and medical device-oriented venture capital investor in the US and Europe for over a decade, previously with Endeavour Vision, a Geneva-based growth stage venture fund, investing in medical devices and digital health companies, and at Sofinnova Partners, a leading Paris based life sciences VC, investing in medical technologies. In her prior roles she served on several medical device boards including ReCor Medical (sold to Otsuka Holdings), Shockwave Medical (NASDAQ: SWAV, sold to JNJ in 2024), and RefleXion Medical.

Prior to VC, Katie held roles in Business Development, Sales and Marketing at Medtronic in the Cardiac and Vascular businesses both in the US and in Europe. She began her career at McKinsey & Company and Partners Healthcare in Boston. Katie holds a M.B.A. in Healthcare Management from the Wharton School at the University of Pennsylvania and a B.A. cum laude in International Relations and Political Science from Yale University.